NBIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Neurocrine Biosciences's enterprise value is $13,075 Mil. Neurocrine Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,887 Mil. Therefore, Neurocrine Biosciences's EV-to-Revenue for today is 6.93.
The historical rank and industry rank for Neurocrine Biosciences's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Neurocrine Biosciences was 4289.94. The lowest was 5.14. And the median was 17.86.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-04-27), Neurocrine Biosciences's stock price is $135.99. Neurocrine Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $18.82. Therefore, Neurocrine Biosciences's PS Ratio for today is 7.22.
The historical data trend for Neurocrine Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 12.36 | 8.20 | 6.89 | 7.25 | 6.57 |
Neurocrine Biosciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 7.25 | 5.78 | 5.08 | 5.73 | 6.57 |
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Neurocrine Biosciences's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 13074.742 | / | 1887.1 | |
= | 6.93 |
Neurocrine Biosciences's current Enterprise Value is $13,075 Mil.
Neurocrine Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,887 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (NAS:NBIX) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Neurocrine Biosciences's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 135.99 | / | 18.823 | |
= | 7.22 |
Neurocrine Biosciences's share price for today is $135.99.
Neurocrine Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.82.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Neurocrine Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Charles Gorman | officer: Sr VP, Business Development | 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
William H Rastetter | director | 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121 |
Kyle Gano | officer: Chief Business Dev Officer | NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Eiry Roberts | officer: Chief Medical Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130 |
Julie Cooke | officer: Chief Human Resources Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Gary A Lyons | director, officer: President and CEO | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Darin Lippoldt | officer: Chief Legal Officer | C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Jude Onyia | officer: Chief Scientific Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
David W. Boyer | officer: Chief Corp. Affairs Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Ingrid Delaet | officer: Chief Regulatory Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130 |
Matt Abernethy | officer: Chief Financial Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121 |
Eric Benevich | officer: Chief Commerical Officer | C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130 |
Christine A Poon | director | C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
Malcolm Lloyd-smith | officer: Chief Regulatory Officer | 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Stephen A Sherwin | director | C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocus Research • 12-12-2023
By PRNewswire • 11-14-2023
By PRNewswire • 11-14-2023
By PRNewswire • 01-02-2024
By GuruFocus Research • 09-14-2023
By PRNewswire • 11-14-2023
By GuruFocus Research • 12-25-2023
By GuruFocus Research • 01-05-2024
By GuruFocus Research • 12-23-2023
By GuruFocus Research • 12-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.